Related Experiment Video
Updated: May 8, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Exposure to the new Medicare Advantage risk adjustment model varies across insurers
Jeffrey Marr1, Andrew M Ryan1, David J Meyers1
1Department of Health Services, Policy and Practice, Brown University School of Public Health, Providence, RI 02903, USA.
Introduction:
Medicare Advantage plan payment depends on the health of enrolled patients. As a result, the extent to which beneficiary clinical severity is documented administratively-known as coding intensity-is greater in Medicare Advantage (MA) than in traditional Medicare, which inflates payment to plans. In 2024, the Centers for Medicare and Medicaid Services began phasing in a new risk adjustment model intended to reduce the susceptibility of MA payments to higher coding intensity.
Methods:
Using 2021 data, we compared average MA contract risk scores under the new model and the old model.
Results:
Risk scores were 5.8% lower under the new risk adjustment model. Differences between average risks scores under the new and old model varied substantially across contracts and insurers. For example, 1 large insurer's risk scores were essentially unchanged across models while another large insurer's risk score was 18% lower under the new model. Contracts with higher estimated coding intensity had greater exposure to the new risk adjustment model.
Conclusion:
Our results suggest that the new risk adjustment model will likely reduce MA payments due to enhanced coding intensity, with these reductions appropriately targeting insurers that code more intensely.
Related Concept Videos
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic illness...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Relative Risk
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Dosage Regimen: Individualization
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
